Table 2.
Associations between the change in performance measures and blood pressure after sequential covariate adjustment.
| Outcomes |
||
|---|---|---|
| Systolic blood pressure β (95% CI) |
Diastolic blood pressure β (95% CI) |
|
| Model 1 | ||
| Grip strength | 0.88 (0.37, 1.40) ‡ | 0.69 (0.39, 0.98) ∥ |
| Chair stand | 0.22 (−0.02, 0.47) | 0.07 (−0.03, 0.17) |
| Gait speed | 0.61 (0.12, 1.10) † | 0.71 (0.42, 0.99) ∥ |
| Model 2 | ||
| Grip strength | 0.62 (0.09, 1.15) † | 0.41 (0.10, 0.71) ‡ |
| Chair stand | 0.18 (−0.04, 0.40) | 0.01 (−0.05, 0.07) |
| Gait speed | 0.78 (0.26, 1.30) ‡ | 0.59 (0.28, 0.90) ∥ |
| Model 3 | ||
| Grip strength | 0.59 (0.06, 1.11) † | 0.35 (0.04, 0.65) † |
| Chair stand | 0.17 (−0.05, 0.38) | 0.00 (−0.06, 0.06) |
| Gait speed | 0.74 (0.22, 1.26) ‡ | 0.55 (0.24, 0.85) ‡ |
Notes:
point estimates express the association between one standardized unit change in each performance measure and the associated BP change.
Significance
p<0.05;
p<0.01;
p<0.0001.
Model 1: age, race and ethnicity, clinic site, education.
Model 2: Model 1+ smoking status, alcohol use, cognitive function (Teng 3MS), self-rated health (SF12), time-varying physical activity (PASE score) and BMI (calculated using data from baseline, year 7 and 9 follow-up time points), prior fall, presence of at least one comorbidity (yes/no, osteoarthritis, COPD, kidney disease/failure, diabetes).
Model 3: Model 2 + CVD + time-varying duration of antihypertensive medication usage (calculated as the maximum value of a duration at each time point).